Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Inflammation stimulates the expression of PCSK9.

Feingold KR, Moser AH, Shigenaga JK, Patzek SM, Grunfeld C.

Biochem Biophys Res Commun. 2008 Sep 19;374(2):341-4. doi: 10.1016/j.bbrc.2008.07.023. Epub 2008 Jul 16.

2.

Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo.

Schmidt RJ, Beyer TP, Bensch WR, Qian YW, Lin A, Kowala M, Alborn WE, Konrad RJ, Cao G.

Biochem Biophys Res Commun. 2008 Jun 13;370(4):634-40. doi: 10.1016/j.bbrc.2008.04.004. Epub 2008 Apr 10.

PMID:
18406350
3.

Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor.

Lambert G, Jarnoux AL, Pineau T, Pape O, Chetiveaux M, Laboisse C, Krempf M, Costet P.

Endocrinology. 2006 Oct;147(10):4985-95. Epub 2006 Jun 22.

PMID:
16794006
4.

Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9.

Kourimate S, Le May C, Langhi C, Jarnoux AL, Ouguerram K, Zaïr Y, Nguyen P, Krempf M, Cariou B, Costet P.

J Biol Chem. 2008 Apr 11;283(15):9666-73. doi: 10.1074/jbc.M705831200. Epub 2008 Feb 3.

5.

Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2.

Jeong HJ, Lee HS, Kim KS, Kim YK, Yoon D, Park SW.

J Lipid Res. 2008 Feb;49(2):399-409. Epub 2007 Oct 5.

6.

Berberine inhibits dyslipidemia in C57BL/6 mice with lipopolysaccharide induced inflammation.

Xiao HB, Sun ZL, Zhang HB, Zhang DS.

Pharmacol Rep. 2012;64(4):889-95.

7.

PCSK9: an enigmatic protease.

Lopez D.

Biochim Biophys Acta. 2008 Apr;1781(4):184-91. doi: 10.1016/j.bbalip.2008.01.003. Epub 2008 Feb 2. Review.

PMID:
18280815
8.

Local effects of human PCSK9 on the atherosclerotic lesion.

Giunzioni I, Tavori H, Covarrubias R, Major AS, Ding L, Zhang Y, DeVay RM, Hong L, Fan D, Predazzi IM, Rashid S, Linton MF, Fazio S.

J Pathol. 2016 Jan;238(1):52-62. doi: 10.1002/path.4630. Epub 2015 Nov 13.

9.

Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.

Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamelin J, Tremblay M, Jacques H, Jin W, Davignon J, Seidah NG, Prat A.

Hepatology. 2008 Aug;48(2):646-54. doi: 10.1002/hep.22354.

PMID:
18666258
10.

The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2.

Poirier S, Mayer G, Benjannet S, Bergeron E, Marcinkiewicz J, Nassoury N, Mayer H, Nimpf J, Prat A, Seidah NG.

J Biol Chem. 2008 Jan 25;283(4):2363-72. Epub 2007 Nov 26.

11.

Berberine decreases PCSK9 expression in HepG2 cells.

Cameron J, Ranheim T, Kulseth MA, Leren TP, Berge KE.

Atherosclerosis. 2008 Dec;201(2):266-73. doi: 10.1016/j.atherosclerosis.2008.02.004. Epub 2008 Feb 15.

PMID:
18355829
12.

PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion.

Langhi C, Le May C, Gmyr V, Vandewalle B, Kerr-Conte J, Krempf M, Pattou F, Costet P, Cariou B.

Biochem Biophys Res Commun. 2009 Dec 25;390(4):1288-93. doi: 10.1016/j.bbrc.2009.10.138. Epub 2009 Oct 28.

PMID:
19878649
13.
14.

Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia.

Lopez D.

Drug News Perspect. 2008 Jul-Aug;21(6):323-30. doi: 10.1358/dnp.2008.21.6.1246795. Review.

PMID:
18836590
15.

Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c.

Costet P, Cariou B, Lambert G, Lalanne F, Lardeux B, Jarnoux AL, Grefhorst A, Staels B, Krempf M.

J Biol Chem. 2006 Mar 10;281(10):6211-8. Epub 2006 Jan 6.

16.

PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain.

Liu M, Wu G, Baysarowich J, Kavana M, Addona GH, Bierilo KK, Mudgett JS, Pavlovic G, Sitlani A, Renger JJ, Hubbard BK, Fisher TS, Zerbinatti CV.

J Lipid Res. 2010 Sep;51(9):2611-8. doi: 10.1194/jlr.M006635. Epub 2010 May 7.

17.

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice.

Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, Anderson NN, Ho YK, Hammer RE, Horton JD.

J Clin Invest. 2006 Nov;116(11):2995-3005.

18.

Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.

Maxwell KN, Fisher EA, Breslow JL.

Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):2069-74. Epub 2005 Jan 27.

19.

Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia.

Maxwell KN, Breslow JL.

Curr Opin Lipidol. 2005 Apr;16(2):167-72. Review.

PMID:
15767856
20.

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.

Rashid S, Curtis DE, Garuti R, Anderson NN, Bashmakov Y, Ho YK, Hammer RE, Moon YA, Horton JD.

Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5374-9. Epub 2005 Apr 1.

Supplemental Content

Support Center